Drugs / TIAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03791294 | Jan → Jun 2019 | hemorrhagic disease, infectious disease | University of Insubria | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03791294 ↗ |
| Modality | Other / unclassified | “TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract” NCT03791294 ↗ |